Related Experiment Video
Updated: Jun 13, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Towards consensus practices to qualify safety biomarkers for use in early drug development
Frank D Sistare1, Frank Dieterle, Sean Troth
1Merck Research Laboratories, Safety Assessment, West Point, Pennsylvania, USA. frank_sistare@merck.com
Abstract:
Application of any new biomarker to support safety-related decisions during regulated phases of drug development requires provision of a substantial data set that critically assesses analytical and biological performance of that biomarker. Such an approach enables stakeholders from industry and regulatory bodies to objectively evaluate whether superior standards of performance have been met and whether specific claims of fit-for-purpose use are supported. It is therefore important during the biomarker evaluation process that stakeholders seek agreement on which critical experiments are needed to test that a biomarker meets specific performance claims, how new biomarker and traditional comparators will be measured and how the resulting data will be merged, analyzed and interpreted.
Related Concept Videos
Preclinical Development: Overview
Drug Discovery: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacogenomics: Identification of New Drug Targets
Therapeutic Drug Monitoring: Drug Analysis Methods